Listed

Eupraxia Pharmaceuticals Inc.

EPRXNasdaqCIK 1581178HealthcareFiscal year ends Dec 31

Share

Share this page

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Balance sheet

Cash and equivalents$80.6m, FY2025
Shareholders' equity$82.0m, FY2025
Line itemUnitperiod not labelled2021-12-31period not labelled2022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31
Cash and equivalents$mnot reported18.3Cash and equivalents, period not labelled, at 2022-12-31$18.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 40-F filed 2024-04-01, accession 0001193125-24-083584.Report this figure19.3Cash and equivalents, FY2023, at 2023-12-31$19.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 40-F filed 2025-03-20, accession 0001193125-25-059352.Report this figure33.1Cash and equivalents, FY2024, at 2024-12-31$33.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 40-F filed 2026-03-13, accession 0001193125-26-104765.Report this figure80.6Cash and equivalents, FY2025, at 2025-12-31$80.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 40-F filed 2026-03-13, accession 0001193125-26-104765.Report this figure
Current assets$mnot reported18.6Current assets, period not labelled, at 2022-12-31$18.6m. XBRL concept us-gaap:AssetsCurrent. 40-F filed 2024-04-01, accession 0001193125-24-083584.Report this figure19.8Current assets, FY2023, at 2023-12-31$19.8m. XBRL concept us-gaap:AssetsCurrent. 40-F filed 2025-03-20, accession 0001193125-25-059352.Report this figure34.4Current assets, FY2024, at 2024-12-31$34.4m. XBRL concept us-gaap:AssetsCurrent. 40-F filed 2026-03-13, accession 0001193125-26-104765.Report this figure85.1Current assets, FY2025, at 2025-12-31$85.1m. XBRL concept us-gaap:AssetsCurrent. 40-F filed 2026-03-13, accession 0001193125-26-104765.Report this figure
Total assets$mnot reported19.1Total assets, period not labelled, at 2022-12-31$19.1m. XBRL concept us-gaap:Assets. 40-F filed 2024-04-01, accession 0001193125-24-083584.Report this figure20.3Total assets, FY2023, at 2023-12-31$20.3m. XBRL concept us-gaap:Assets. 40-F filed 2025-03-20, accession 0001193125-25-059352.Report this figure34.9Total assets, FY2024, at 2024-12-31$34.9m. XBRL concept us-gaap:Assets. 40-F filed 2026-03-13, accession 0001193125-26-104765.Report this figure86.2Total assets, FY2025, at 2025-12-31$86.2m. XBRL concept us-gaap:Assets. 40-F filed 2026-03-13, accession 0001193125-26-104765.Report this figure
Current liabilities$mnot reported3.1Current liabilities, period not labelled, at 2022-12-31$3.1m. XBRL concept us-gaap:LiabilitiesCurrent. 40-F filed 2024-04-01, accession 0001193125-24-083584.Report this figure19.4Current liabilities, FY2023, at 2023-12-31$19.4m. XBRL concept us-gaap:LiabilitiesCurrent. 40-F filed 2025-03-20, accession 0001193125-25-059352.Report this figure3.1Current liabilities, FY2024, at 2024-12-31$3.1m. XBRL concept us-gaap:LiabilitiesCurrent. 40-F filed 2026-03-13, accession 0001193125-26-104765.Report this figure5.6Current liabilities, FY2025, at 2025-12-31$5.6m. XBRL concept us-gaap:LiabilitiesCurrent. 40-F filed 2026-03-13, accession 0001193125-26-104765.Report this figure
Total liabilities$mnot reported11.9Total liabilities, period not labelled, at 2022-12-31$11.9m. XBRL concept us-gaap:Liabilities. 40-F filed 2024-04-01, accession 0001193125-24-083584.Report this figure19.4Total liabilities, FY2023, at 2023-12-31$19.4m. XBRL concept us-gaap:Liabilities. 40-F filed 2025-03-20, accession 0001193125-25-059352.Report this figure3.1Total liabilities, FY2024, at 2024-12-31$3.1m. XBRL concept us-gaap:Liabilities. 40-F filed 2026-03-13, accession 0001193125-26-104765.Report this figure5.7Total liabilities, FY2025, at 2025-12-31$5.7m. XBRL concept us-gaap:Liabilities. 40-F filed 2026-03-13, accession 0001193125-26-104765.Report this figure
Shareholders' equity$m15.1Shareholders' equity, period not labelled, at 2021-12-31$15.1m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 40-F filed 2024-04-01, accession 0001193125-24-083584.Report this figure7.8Shareholders' equity, period not labelled, at 2022-12-31$7.8m. XBRL concept us-gaap:StockholdersEquity. 40-F filed 2024-04-01, accession 0001193125-24-083584.Report this figure2.2Shareholders' equity, FY2023, at 2023-12-31$2.2m. XBRL concept us-gaap:StockholdersEquity. 40-F filed 2025-03-20, accession 0001193125-25-059352.Report this figure33.4Shareholders' equity, FY2024, at 2024-12-31$33.4m. XBRL concept us-gaap:StockholdersEquity. 40-F filed 2026-03-13, accession 0001193125-26-104765.Report this figure82.0Shareholders' equity, FY2025, at 2025-12-31$82.0m. XBRL concept us-gaap:StockholdersEquity. 40-F filed 2026-03-13, accession 0001193125-26-104765.Report this figure

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. Listed shows no prices and gives no investment advice.